184) Alaska Native people are under-represented in genetic research but have unique gene variation that may critically impact their response to pharmacotherapy. |
PMID:33632714 DOI:10.1124/dmd.120.000301 |
2021 Drug metabolism and disposition: the biological fate of chemicals |
* In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup'ik Alaska Native Population. |
- Alaska Native people are under-represented in genetic research but have unique gene variation that may critically impact their response to pharmacotherapy. Full resequencing of CYP2C9 in a cross-section of this population identified CYP2C9 Met1Leu (M1L), a novel, relatively common single nucleotide polymorphism hypothesized to confer CYP2C9 poor metabolizer phenotype by disrupting the start codon. M1L is present at a minor allele frequency of 6.3% in Yup'ik Alaska Native people and thus can contribute to the risk of an adverse drug response from narrow-therapeutic-index CYP2C9 substrates such as (S)-warfarin. This study's objective was to characterize the catalytic efficiency of the Leu1 variant enzyme in vivo by evaluating the pharmacokinetic behavior of naproxen, a probe substrate for CYP2C9 activity, in genotyped Yup'ik participants. We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity-phenotyped human liver microsomes and selective cytochrome P450 inhibitors and then developed and validated a novel liquid chromatography mass spectrometry method for simultaneous quantification of (S)-naproxen, (S)-O-desmethylnaproxen, and naproxen acyl glucuronide in human urine. The average ratio of (S)-O-desmethylnaproxen to unchanged (S)-naproxen in urine was 18.0 ± 8.0 (n = 11) for the homozygous CYP2C9Met1 reference group and 10.3 ± 6.6 (n = 11) for the Leu1 variant carrier group (P = 0.011). The effect of M1L variation on CYP2C9 function and its potential to alter the pharmacokinetics of drugs metabolized by the enzyme has clinical implications and should be included in a variant screening panel when pharmacogenetic testing in the Alaska Native population is warranted. SIGNIFICANCE STATEMENT: The novel CYP2C9 Met1Leu variant in Alaska Native people was recently identified. This study validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant. The results of this pharmacogenetic-pharmacokinetic study suggest that the CYP2C9 Leu1 variant exhibits loss of enzyme activity. This finding may be important to consider when administering narrow-therapeutic-index medications metabolized by CYP2C9 and also compels further investigation to characterize novel genetic variation in understudied populations. |
(1)136 ![]() |
(18)4 ![]() |
(35)2 ![]() |
(52)2 ![]() |
(2)13 ![]() |
(19)4 ![]() |
(36)2 ![]() |
(53)2 ![]() |
(3)10 ![]() |
(20)4 ![]() |
(37)2 ![]() |
(54)2 ![]() |
(4)8 *null* | (21)4 ![]() |
(38)2 ![]() |
(55)2 ![]() |
(5)7 ![]() |
(22)3 ![]() |
(39)2 ![]() |
(56)2 ![]() |
(6)7 ![]() |
(23)3 ![]() |
(40)2 ![]() |
(57)2 ![]() |
(7)6 ![]() |
(24)3 ![]() |
(41)2 ![]() |
(58)2 ![]() |
(8)6 ![]() |
(25)3 ![]() |
(42)2 ![]() |
(59)2 ![]() |
(9)6 ![]() |
(26)3 ![]() |
(43)2 ![]() |
(60)2 ![]() |
(10)5 ![]() |
(27)3 ![]() |
(44)2 ![]() |
(61)2 ![]() |
(11)5 ![]() |
(28)3 ![]() |
(45)2 ![]() |
(62)2 ![]() |
(12)5 ![]() |
(29)3 ![]() |
(46)2 ![]() |
(63)2 ![]() |
(13)4 ![]() |
(30)3 ![]() |
(47)2 ![]() |
(64)2 ![]() |
(14)4 ![]() |
(31)3 ![]() |
(48)2 ![]() |
(65)2 ![]() |
(15)4 ![]() |
(32)3 ![]() |
(49)2 ![]() |
|
(16)4 ![]() |
(33)2 ![]() |
(50)2 ![]() |
|
(17)4 ![]() |
(34)2 ![]() |
(51)2 ![]() |
add keyword